[Federal Register Volume 78, Number 228 (Tuesday, November 26, 2013)]
[Notices]
[Pages 70531-70532]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-28353]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign Trade Zones Board
[B-98-2013]
Foreign-Trade Zone (FTZ) 93--Raleigh/Durham, North Carolina;
Notification of Proposed Production Activity; GlaxoSmithKline, PLC
(Pharmaceutical Products); Zebulon, North Carolina
The Triangle J Council of Governments, grantee of FTZ 93, submitted
a notification of proposed production activity to the FTZ Board on
behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon,
North Carolina. The notification conforming to the requirements of the
regulations of the FTZ Board (15 CFR 400.22) was received on November
18, 2013.
The GlaxoSmithKline facility is located within Site 6 of FTZ 93.
The facility is used for the production and packaging of pharmaceutical
products. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited
to the specific foreign-status materials and components and specific
finished products listed in the submitted notification (as described
below) and subsequently authorized by the FTZ Board.
Production under FTZ procedures could exempt GlaxoSmithKline from
[[Page 70532]]
customs duty payments on the foreign status components used in export
production. On its domestic sales, GlaxoSmithKline would be able to
choose the duty rates during customs entry procedures that apply to
inhalers, tablets, and capsules which treat a variety of medical
conditions (duty rates range from free to 6.4%) for the foreign status
inputs noted below. Customs duties also could possibly be deferred or
reduced on foreign status production equipment.
The finished products include devices such as respiratory placebo
inhalers, Relenza anti-viral inhalers, Seretide/Advair, Serevent and
Flovent diskus respiratory inhalers, Advair and Ventolin HFA
respiratory inhalers, and the following tablets and capules--Lovaza
antihyperlipidemic, Paxil depression, Avandamet metabolic, Avandary
metabolic, Avandia metabolic, Lamictal central nervous system (CNS),
Potiga CNS, Amerge CNS, Horizant CNS, Imitrex CNS, Lamictal ODT CNS,
Requip/Requip XL CNS, Treximet CNS, Telzir anti-viral, Valtrex anti-
viral, Zovirax anti-viral, Wellbutrin/Buproprion depression, Zantac
gastrointestinal (GI), Zofran GI, Votrient urology, Coreg CR
cardiovascular, Rythmol cardiovascular, Innopran XL hypertension, Jalyn
urology, Avodart urology, Lanoxin cardiovascular, Malarone anti-
malarial, Promacta immune thrombocytopenia (ITP), and Tykerb oncology.
The components and materials sourced from abroad include corn
starch, carnuba wax, lactose monohydrate, fluticasone/salmeterol
placebo diskus (a type of inhaler), respiratory placebo inhaler, silica
colloidal anhydrous, precipitated calcium carbonate, pharmaceutical
talc, zephex 134a propellant, mannitol, magnesium stearate, stearic
acid, potassium sorbate, propafenon hcl, bupropion hydrochloride,
melphalan, albuterol sufate, salbuterol sulfate, salmeterol, vilanterol
trifenatate, umeclidinium api, paracetamol, ezogabine (retigabine),
paracetamol, metformin hydrochloride, ranitidine hydrochloride,
zanamivir, ondansetron hydrochloride, abacavir sulfate, valacyclovir
hydrochloride, lamotrigine, rosiglitazone maleate, paroxetine
hydrochloride, lamivudine, zidovudine, pazopanib, fluticasone
propionate, fluticasone furoate, dutasteride, Lovaza capsules, breo
ellipta inhalers, avodart capsules, flovent diskus, Paxil tablets,
lexiva oral suspension, sumatriptan succinate/naproxen (Treximet),
abacavir/lamivudine tablets (epzicom) tablets, atovaquone and proguanil
hcl tablets, combivir tablets, dolutegravir tablets, epivir tablets,
epzicom tablets, malarone tablets, ziagen tablets, Zantac tablets,
mekinist tablets, trametinib tablets, pazopanib tablets, tafinlar
capsules, votrient tablets, coreg cr capsules, flolan for injection,
propafenon sr, Rythmol (proafenon) sr, Amerge tablets, imigran
injection, imitrex bulk pack, sumatriptan succinate 85mg/naproxen,
lamictal, parnate tablets, ondansetron odt bulk, requip tablets,
soriatane (acitretin) capsules, Zofran, Ventolin actuator dose counter,
Advair diskus, Advair diskus inhalation powder, fluticasone/salmeterol
aerosol inhalers, Ventolin samples, Seretide, argatroban, arixtra,
Avandamet tablets, Avandia tablets, dutasteride-tamsulosin hcl fdc
capsules, eltrombopag, flolan sterile diluent, Jalyn fixed dose
combination capsules, panadol tablets, opadry (an excipient), starch
pregel, Avandamet placebo tablets, placebo diskus, nasal spray demo
pack, respiratory placebo, triacetin, crospovidone, povidone,
spectracel, alginic acid ep, 20 micron aluminum powder, empty aerosol
cans, pressure can spray valves, diskus subassemblies, multi-dose
powder inhalers, novel dry powder inhalers, multi-dose powder inhaler
subassembly and placebo, multi-dose powder inhaler diskus devices,
actuators--and their dose counters and assemblies (duty rates range
from free to 6.5%).
Public comment is invited from interested parties. Submissions
shall be addressed to the FTZ Board's Executive Secretary at the
address below. The closing period for their receipt is January 6, 2014.
A copy of the notification will be available for public inspection
at the Office of the Executive Secretary, Foreign-Trade Zones Board,
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW.,
Washington, DC 20230-0002, and in the ``Reading Room'' section of the
FTZ Board's Web site, which is accessible via www.trade.gov/ftz.
For further information, contact
Diane.Finver[com x mat]trade.gov or (202) 482-1367.
Dated: November 19, 2013.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2013-28353 Filed 11-25-13; 8:45 am]
BILLING CODE 3510-DS-P